All conditions

Ankylosing Spondylitis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

480
Trials on record
50
Recruiting now
1
Australian sites
7
Phase 3 trials
10
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Ankylosing Spondylitis →

Get alerts when Ankylosing Spondylitis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a type of inflammatory arthritis that mainly affects the spine and the joints connecting the spine to the pelvis, known as the sacroiliac joints. In AS, the immune system mistakenly causes inflammation in these areas, which can lead to pain, stiffness, and reduced movement, particularly in the lower back. Over time and without management, some people find that the inflammation causes new bone to form, which can gradually fuse sections of the spine together. Symptoms often start in early adulthood, and many people notice that stiffness is worse after rest or in the morning and tends to ease with gentle movement.

In Australia, AS is estimated to affect around one in 200 people, making it more common than many people realise. It was historically thought to affect men more than women, though it is now understood that women are also significantly affected, sometimes with slightly different symptoms that can make diagnosis less straightforward. There is often a strong genetic link, with a gene marker called HLA-B27 present in many people with the condition, though not everyone who carries this gene will develop AS.

Treatment in Australia is generally overseen by a rheumatologist and tends to focus on reducing inflammation, managing pain, and maintaining as much movement and function as possible. Physiotherapy and regular exercise are considered important parts of managing the condition. Medications commonly used include anti-inflammatory drugs, and for people whose symptoms do not respond well to these, there are other medication options available through the PBS. Regular check-ins with a healthcare team allow treatment to be adjusted over time based on how the condition is progressing.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Ankylosing Spondylitis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Ankylosing Spondylitis

10 medicines listed on the PBS for Ankylosing Spondylitis. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 10 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Adalimumab Humira, Hadlima, Hyrimoz +1 more Ankylosing spondylitis AU$444.17 Authority required
bimekizumab Bimzelx Ankylosing spondylitis AU$3260 Authority required
Certolizumab pegol Cimzia Ankylosing spondylitis AU$938.04 Authority required
Etanercept Enbrel, Brenzys Ankylosing spondylitis AU$371.81 Authority required
Golimumab Simponi Ankylosing spondylitis AU$939.99 Authority required
Infliximab Remsima SC, Inflectra Ankylosing spondylitis AU$186.16 Authority required
Ixekizumab Taltz Ankylosing spondylitis AU$3097 Authority required
Secukinumab Cosentyx Ankylosing spondylitis AU$625.37 Authority required
Tofacitinib Xeljanz Ankylosing spondylitis AU$1037.85 Authority required
Upadacitinib Rinvoq Ankylosing spondylitis AU$1092.47 Authority required
bimekizumab Bimzelx Non-radiographic axial spondyloarthritis AU$3260 Authority required
Certolizumab pegol Cimzia Non-radiographic axial spondyloarthritis AU$938.04 Authority required
Golimumab Simponi Non-radiographic axial spondyloarthritis AU$939.99 Authority required
Secukinumab Cosentyx Non-radiographic axial spondyloarthritis AU$625.37 Authority required
Upadacitinib Rinvoq Non-radiographic axial spondyloarthritis AU$1092.47 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Ankylosing Spondylitis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Ankylosing Spondylitis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Ankylosing Spondylitis by country. Australia is highlighted.

Showing the top 10 of 48 countries with trial sites.

Clinical trials for Ankylosing Spondylitis

Showing 62 of 62 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00247962 · Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 · 18 countries Completed
Completed Phase 4 Est. completion 1 February 2008
🇦🇺 AU🇦🇹 AT🇨🇳 CN🇨🇿 CZ🇩🇰 DK🇫🇮 FI🇫🇷 FR🇩🇪 DE +10 more

Who might be able to join this trial: - You have been diagnosed by a doctor with a condition called ankylosing spondylitis (a type of inflammatory arthritis that mainly affects the spine) - Your ankylosing spondylitis is currently active (meaning you are experiencing ongoing symptoms) Who may not be able to join: - Yo...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT01061723 · Sanofi Phase 2 · 14 countries Completed
Completed Phase 2 Est. completion 1 June 2011
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU +6 more

**Who might be able to join this trial:** - You have been diagnosed with Ankylosing Spondylitis (AS) using standard medical criteria known as the "New York modified criteria." - You have tried at least 2 different anti-inflammatory pain medications (like ibuprofen or naproxen) for at least 2 weeks each, or you are una...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01583374 · Amgen Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 24 February 2014
🇦🇺 AU🇦🇹 AT🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇪🇪 EE🇫🇷 FR🇩🇪 DE +10 more

"Who might be able to join this trial: - You must have a confirmed diagnosis of ankylosing spondylitis (AS), a type of inflammatory arthritis affecting the spine, with back pain and stiffness that has lasted more than 3 months, gets better with movement, but does not go away with rest. - Your AS must be confirmed as "d...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02159053 · Novartis Pharmaceuticals Phase 3 · 19 countries Completed
Completed Phase 3 Est. completion 23 February 2016
🇦🇺 AU🇦🇹 AT🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇮 FI🇩🇪 DE +11 more

Who might be able to join this trial: - You have been diagnosed with moderate to severe ankylosing spondylitis (a type of inflammatory spinal arthritis) - Past X-rays have confirmed your diagnosis based on specific medical imaging guidelines from 1984 (confirm with trial site) - Pain relief medications known as NSAIDs...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02509026 · Pfizer Phase 4 · 14 countries Completed
Completed Phase 4 Est. completion 28 May 2019
🇦🇺 AU🇧🇪 BE🇨🇴 CO🇨🇿 CZ🇫🇮 FI🇫🇷 FR🇩🇪 DE🇭🇺 HU +6 more

Who might be able to join this trial: - You have been diagnosed with axial spondyloarthritis (a type of inflammatory back condition affecting the spine) - Your symptoms have lasted more than 3 months but less than 5 years - You have back pain that has not improved enough with anti-inflammatory painkillers (such as ibup...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT02552212 · UCB BIOSCIENCES GmbH Phase 3 · 9 countries Completed
Completed Phase 3 Est. completion 1 May 2018
🇦🇺 AU🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇭🇺 HU🇵🇱 PL🇷🇺 RU🇹🇼 TW +1 more

**Who might be able to join this trial:** - You are at least 18 years old at the start of the screening process - You have been diagnosed with a specific type of back-related arthritis called axial spondyloarthritis (axSpA), confirmed using recognised international guidelines - You have had back pain for at least 12 m...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02696031 · Novartis Pharmaceuticals Phase 3 · 24 countries Completed
Completed Phase 3 Est. completion 1 July 2019
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU +16 more

Who might be able to join this trial: - You are male, or a female who is not pregnant and not breastfeeding, and you are at least 18 years old - You have been diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) based on recognised international diagnostic standards - Your condi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03259074 · Novartis Pharmaceuticals Phase 3 · 29 countries Completed
Completed Phase 3 Est. completion 12 November 2021
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇱 CL🇨🇴 CO🇨🇿 CZ🇩🇰 DK +21 more

**Who might be able to join this trial:** - You are male, or a female who is not pregnant or breastfeeding, and you are at least 18 years old - You have been diagnosed with moderate to severe Ankylosing Spondylitis (a type of spinal arthritis) confirmed by X-ray, and standard anti-inflammatory or non-biologic medicatio...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03502616 · Pfizer Phase 3 · 14 countries Completed
Completed Phase 3 Est. completion 19 December 2019
🇦🇺 AU🇧🇬 BG🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇭🇺 HU🇮🇱 IL +6 more

Who might be able to join this trial: - You have been diagnosed with Ankylosing Spondylitis (AS) based on specific diagnostic guidelines called the Modified New York Criteria (1984). - You have had an X-ray of your pelvis that confirms your diagnosis of AS. - Your AS is still causing significant symptoms even while tak...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04169373 · AbbVie Phase 3 · 25 countries Completed
Completed Phase 3 Est. completion 2 September 2021
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇳 CN🇨🇿 CZ +17 more

**Who might be able to join this trial:** **For Study 1 (Ankylosing Spondylitis):** - You must have been diagnosed with ankylosing spondylitis (AS) and meet specific standard medical criteria for this condition. - Your spine must not be completely fused/locked together from the disease. - You must have previously trie...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07047703 · Grey Wolf Therapeutics Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 30 April 2028
🇦🇺 AU🇧🇪 BE🇩🇪 DE🇳🇱 NL🇵🇱 PL🇪🇸 ES

**Who might be able to join this trial:** **For healthy volunteers:** - You are a man or woman aged 18 to 55 years old at the time of your screening appointment - You are willing and able to sign a consent form agreeing to take part in the study - You are able and willing to follow all the study rules, including any f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01209702 · Hoffmann-La Roche Phase 3 · 18 countries Terminated
Terminated Phase 3 Est. completion 1 May 2011
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE +10 more

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with Ankylosing Spondylitis (a type of spinal arthritis) for at least 3 months before the study start date, based on specific medical criteria - Your condition is currently active, meaning your symptoms and spinal pai...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02407223 · Janssen Research & Development, LLC Phase 3 · 14 countries Terminated
Terminated Phase 3 Est. completion 26 September 2017
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU🇲🇽 MX +6 more

**Who might be able to join this trial:** - You have been diagnosed with a condition called non-radiographic axial spondyloarthritis (nr-AxSpA) based on specific international guidelines (confirm with trial site) - Your symptoms of nr-AxSpA first appeared when you were 45 years old or younger - An MRI scan shows active...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01422694 · National Institute of Arthritis and Musculoskeletal and Skin Diseases... Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with, or are suspected of having, a condition called spondyloarthropathy (SpA), which is a type of inflammatory joint disease. - Family members of people who have or are suspected of having SpA. - Healthy individuals who are willing to provide b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03425812 · The First Affiliated Hospital of Xiamen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are able to understand and agree to take part, and are willing to follow the study schedule - You have been diagnosed with a type of spinal arthritis called axial spondyloarthritis (axSpA), confirmed using recognised international guidelines - Your axSpA is currently in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03839862 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇸🇪 SE

Who might be able to join this trial: - People who have been diagnosed with a type of inflammatory arthritis called spondyloarthropathy, based on a recognised set of international classification standards - People who are about to start a type of medication known as a TNF-inhibitor (a biologic drug that reduces inflamm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04274374 · University Hospital, Clermont-Ferrand Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with axial spondyloarthritis (a type of inflammatory joint disease affecting the spine) according to recognised medical guidelines - Your rheumatologist (joint specialist) does not plan to change your treatment during the 4 months after joining the tri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04489342 · Western Health and Social Care Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 January 2026
🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with a spine condition called axial spondyloarthritis, confirmed using standard classification guidelines. - You are aged 18 or older but younger than 80. - You meet the local medical requirements to receive a type of medication called biologic therapy for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05290363 · Institut Pasteur Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are an adult (over 18 years old) - You have been diagnosed with a type of inflammatory arthritis called Spondyloarthritis (SpA), confirmed using recognised medical guidelines - Your condition is currently active, meaning you have swollen or inflamed joints, tendon inflam...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05303285 · Tongji Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with ankylosing spondylitis (AS) and meet a specific set of recognised diagnostic standards for this condition. - Your disease is currently active, meaning your symptoms score 4 or higher (out of 10) on two standard AS activity questionnaires, measure...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05592574 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2041
🇫🇷 FR

"Who might be able to join this trial: - You have been diagnosed with a condition called spondyloarthritis, confirmed using a recognised set of medical guidelines called the ASAS criteria. - Your doctor has decided you need to start a biological treatment (a type of medication made from living cells) because at least t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05603728 · Exactech Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇦 CA🇫🇷 FR🇮🇹 IT🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been recommended for shoulder replacement surgery, or you have already had shoulder replacement surgery in the past - Your bones have finished growing (you are a skeletally mature adult) - You are expected to live for at least 2 years after the surgery - You are will...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05654753 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are between 18 and 75 years old and have been diagnosed with axial spondyloarthritis (a type of inflammatory spine condition), with or without changes visible on an X-ray. - Your condition is still active — meaning your symptoms score 4 or higher (out of 10) on a standar...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05676775 · The Leeds Teaching Hospitals NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 January 2026
🇬🇧 GB

Who might be able to join this trial: - You are 16 years old or older. - A doctor has diagnosed you with axial spondyloarthritis (a type of inflammatory back condition, which includes ankylosing spondylitis) within the last 6 months before the study begins. - You are willing and able to agree to take part in the study...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05781763 · Halmstad University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇪 SE

Who might be able to join this trial: - You have been diagnosed with axial spondyloarthritis (a type of inflammatory back condition) with a specific diagnosis code from your doctor (confirm with trial site) - You are currently meeting the recommended guidelines for physical activity Who may not be able to join: - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05835518 · Yuhan Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇰🇷 KR

**Who might be able to join this trial:** - You are between the ages of 19 and 75 (over 19 and under 75) at the time of signing up for the study - You have been diagnosed with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) for at least 3 months before joining the study - Your doctor has decided that you shoul...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06000956 · Tasly Pharmaceutical Group Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (inclusive), of any gender - You have been diagnosed with axial osteoarthritis (a type of spinal joint disease) based on 2009 ASAS guidelines, and your condition is currently active, shown by specific scores on two pain and disease activity...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06076083 · Tae-Hwan Kim Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇰🇷 KR

**Who might be able to join this trial:** *If you have ankylosing spondylitis:* - You are between 19 and 60 years old at the time of signing up - You have been diagnosed with ankylosing spondylitis based on recognised medical diagnostic criteria (confirm with trial site) - You are willing to take part voluntarily, und...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06083090 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 February 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older and speak French - You have been diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) by a rheumatologist - Your condition is currently rated as "moderately active" to "active" based on a standard symptom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06112665 · Charite University, Berlin, Germany Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2025
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with a condition called axial spondyloarthritis (axSpA) and meet the standard classification guidelines for this condition. - You have had back pain symptoms for 2 years or less, fitting the definition of "early" axial spondyloarthritis. - Your disease...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06222671 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are at least 18 years old (both men and women can apply) - You have been diagnosed with a type of spinal arthritis called axial spondyloarthritis, based on recognised medical guidelines - You have signs of inflammation in your body, shown either by an MRI scan or a blood...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06594107 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2035
🇸🇪 SE

**Who might be able to join this trial:** - You have recently been diagnosed with a condition called axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) - You have not yet received any treatment for this condition - You are 18 years of age or older - You are able to speak and understand Swedi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06642207 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇪🇬 EG

**Who might be able to join this trial:** - You have been diagnosed with a specific type of inflammatory spinal condition called Axial Spondyloarthritis, based on recognised international classification standards. - You have had this condition for more than 6 months. - You have already tried standard treatments that di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06650228 · Kirsehir Ahi Evran Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
Turkey (Türkiye)

Who might be able to join this trial: - You have been diagnosed with ankylosing spondylitis (a type of inflammatory arthritis affecting the spine) based on recognised diagnostic guidelines - You are between 18 and 65 years old - You have been taking the same medications without changes for at least 3 months - You are w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06669702 · Loughborough University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇬🇧 GB

**Who might be able to join this trial:** **If you have axial spondyloarthritis (axSpA):** - You have been diagnosed with axSpA by a specialist rheumatology doctor - You are 18 years old or older - You do not have other significant heart or blood vessel conditions - You are currently on a stable dose of biologic medic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06707194 · Nanfang Hospital, Southern Medical University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to participate. - You are between 18 and 59 years old. - You have been diagnosed with spinal arthritis (also called spondyloarthritis) using recognised medical guidelines — either affecting the spine/pelvis...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06739369 · Kirsehir Ahi Evran Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
Turkey (Türkiye)

Who might be able to join this trial: - You have been diagnosed with ankylosing spondylitis (a type of inflammatory arthritis affecting the spine) based on recognised medical guidelines - You are between 18 and 65 years old - You have been taking the same medications without changes for at least 3 months - You are will...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06807853 · University of Bonn Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with Axial Spondyloarthritis (a type of inflammatory arthritis that mainly affects the spine) - You own a personal iPhone (this is required due to the software used in the study) - You are willing and able to wear a smartwatch throughout the trial - You ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06823726 · Wonju Severance Christian Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) based on recognised classification guidelines. - You are between 19 and 59 years old. - Your medications for this condition have stayed the same for at least the past 3...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06844643 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇨🇳 CN

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with a condition called axial spondyloarthritis (a type of inflammatory arthritis that mainly affects the spine), confirmed using recognised international diagnostic guidelines Who may not be able to join: - You have a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06860750 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2028
🇨🇳 CN

Who might be able to join this trial: - You are 18 years of age or older at the time of signing the consent form, regardless of gender - Your Body Mass Index (BMI — a measure based on your height and weight) is 18 or above at the time of screening - You have measurable signs of inflammation in your body at the time of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06905288 · Novartis Pharmaceuticals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with ankylosing spondylitis (AS) according to a specific set of medical guidelines called the modified 1984 New York criteria - Your AS is currently active, meaning your symptoms are significant enough to score 4 or higher on a standard symptom questio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06967883 · Istanbul Physical Medicine Rehabilitation Training and Research Hospit... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 65 years old. - You have been diagnosed with Ankylosing Spondylitis (a type of inflammatory arthritis affecting the spine) using a specific set of medical guidelines called the Modified New York Criteria (this applies to the patient group). - You are ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06988813 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2030
🇨🇳 CN

**Who might be able to join this trial:** - You received care at Nanfang Hospital, Southern Medical University, at some point between 2010 and 2030. - You are willing to take part and have signed a consent form (for the ongoing part of the study), or you visited the hospital between April 2010 and April 2024 and are no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07133633 · Merck Sharp & Dohme LLC Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 15 June 2027
🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇴 CO🇩🇪 DE🇳🇱 NL🇵🇱 PL +6 more

**Who might be able to join this trial:** - You have been diagnosed with a type of spinal arthritis called axial spondyloarthritis (axSpA), and you have had back pain for at least 3 months that started before you were 45 years old - Your spinal arthritis shows visible changes on X-rays, confirmed by a specialist review...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07141017 · Association de Recherche Clinique en Rhumatologie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

Who might be able to join this trial: - You are an adult under 80 years old who has been diagnosed with a specific type of inflammatory back condition (called axial spondyloarthritis) by a specialist doctor within the last 12 months - You are willing and able to sign a consent form and take part in all parts of the stu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07166874 · Saglik Bilimleri Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - You have been diagnosed with axial spondyloarthritis (a type of inflammatory spinal condition) based on recognised medical criteria (confirm with trial site) - You are between 18 and 64 years old - You have been on a stable medication plan (such as anti-inflammatory or diseas...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07172360 · Jiangsu vcare pharmaceutical technology co., LTD Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 August 2027
🇨🇳 CN

Who might be able to join this trial: - You understand what the trial involves and are willing to sign a consent form agreeing to take part and follow the study rules - You are between 18 and 70 years old (including those ages exactly) at the time of signing the consent form, and any gender is welcome - You have been d...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07237568 · Lynk Pharmaceuticals Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed by a doctor with ankylosing spondylitis (a type of inflammatory arthritis affecting the spine) and meet a specific set of standard diagnostic criteria for this condition. - Your disease activity and back pain have been measured using standard scoring t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07261644 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 14 January 2027
🇨🇳 CN

Who might be able to join this trial: - You are able to understand what the trial involves and are willing to follow the study rules and sign a consent form - You are at least 18 years old (any gender can apply) - You have been diagnosed with ankylosing spondylitis (a type of inflammatory arthritis affecting the spine)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07262294 · Beni-Suef University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇪🇬 EG

Who might be able to join this trial: - You are currently receiving the same medical treatment as other participants in the trial (confirm with trial site) - You are between 20 and 45 years old - You can be either male or female - You have been diagnosed with stable ankylosing spondylitis (a type of inflammatory arthri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07503327 · Inonu University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have been diagnosed with Ankylosing Spondylitis (a type of spinal arthritis) by a specialist at least one year ago - You are willing to take part in the study voluntarily - You own a smartphone and are comfortable using it - You are a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07509775 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with ankylosing spondylitis or axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) according to recognized medical criteria - You are between 18 and 75 years old - You are willing and able to sign a consent form agreeing to t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07510789 · Konya Beyhekim Training and Research Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
Turkey (Türkiye)

Who might be able to join this trial: - You must be 18 years of age or older - You are willing to take part in the study on your own free will - You have been diagnosed with ankylosing spondylitis (a type of inflammatory arthritis that mainly affects the spine) Who may not be able to join: - You are under 18 years of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07535554 · Universitaire Ziekenhuizen KU Leuven Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2029
🇧🇪 BE

Who might be able to join this trial: **If you have a fever of unknown cause:** - You have been ill for more than 3 weeks - You have had a high temperature (above 38.3°C) on more than 3 occasions, or blood tests have shown signs of inflammation on more than 3 occasions - Doctors have not been able to find the cause de...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07556224 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with ankylosing spondylitis or axial spondyloarthritis (a type of inflammatory spinal condition) based on recognized medical criteria (confirm with trial site) - You are between 18 and 75 years old - You are willing and able to sign a consent form agre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07561255 · Wuerzburg University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇪 DE

Who might be able to join this trial: - You must be willing to use a tool or system called "Axia" - You must fall within the area or condition that Axia is intended for (confirm with trial site) - You must be willing to complete a setup/registration process using an onboarding brochure Who may not be able to join: - A...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07578220 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) based on recognised medical criteria (confirm with trial site) - You are between 18 and 75 years old - Your disease activity score (called BASDAI) is 4 or higher, meaning y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07627542 · Merve Şahin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 65 years old. - You use a smartphone for at least 2 hours every day. - You are able to understand and follow instructions about body position during measurements. - For people with Rheumatoid Arthritis (RA): You have been diagnosed with RA by a speciali...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07633730 · Marmara University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 May 2027
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have been diagnosed with a condition called ankylosing spondylitis (a type of inflammatory arthritis affecting the spine), confirmed using a standard set of medical criteria called the Modified New York Criteria - You are already rece...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07642622 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) by a rheumatology specialist. - You speak English. - You are currently not very physically active, meaning you do less than 150 minutes of moderate exercise per week (for e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07724847 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have had ongoing back pain for 3 months or longer, without a clear confirmed cause or diagnosis - People whose back pain first started at age 45 or younger - People who have been referred to a rheumatologist (a joint and inflammation specialist) to investigate a p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Ankylosing Spondylitis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Arthritis Australia covers ankylosing spondylitis as a form of arthritis, and Musculoskeletal Health Australia runs dedicated peer support groups for it.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.